Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0638-0355 · 1 trial · 2 indications
Measured as Number of events
Measured as Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0638-0355 | EXPERIMENTAL | Participants will be randomized to receive NNC0638-0355. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD). |
| Placebo | PLACEBO_COMPARATOR | Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B, C,D and E: Multiple ascending dose (MAD). |
| Name | Type | Description |
|---|---|---|
| NNC0638-0355 | DRUG | NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection. |
| Placebo (NNC0638-0355) | DRUG | Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection. |
Key inclusion criteria * Male or female. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * BMI between 25.0 and 34.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. * Considered to be generally ...
Top 20 of 32 competitors
NNC0638-0355 is an investigational small molecule being developed for the treatment of obesity. It is currently being studied in people living with overweight or obesity. The drug is in Phase 1 clinical development and has not yet been approved by regulatory authorities.
NNC0638-0355 is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for obesity.
NNC0638-0355 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The drug is being studied in a Phase 1 trial to assess its effects in people with overweight or obesity.
NNC0638-0355 is being evaluated in a Phase 1 clinical trial registered as NCT06577766. This randomized, double-blind, placebo-controlled study is investigating how the drug works in people living with overweight or obesity. The trial is active but not recruiting, with an enrollment of 63 participants across the United States and Netherlands.
NNC0638-0355 is a small molecule being developed for obesity. The specific molecular target or mechanism of action has not been disclosed in available information. The drug is currently in Phase 1 clinical trials to evaluate its effects in people with overweight or obesity.